China's medical products administrator approved AIM Vaccine's (HKG:6660) clinical trial application for its mRNA herpes zoster vaccine, according to a Monday disclosure to the Hong Kong bourse.
Third-party pre-clinical tests showed the vaccine's immunity and antibody counts were higher than international commercially available benchmarks, the vaccine manufacturer said.
Shares at the vaccine manufacturer jumped 9% during morning trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.